• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Randomized Trial of Interleukin-2 (IL-2) as Early Consolidation Following Marrow Ablative Therapy with Stem Cell Rescue for Metastatic Breast Cancer
【24h】

Randomized Trial of Interleukin-2 (IL-2) as Early Consolidation Following Marrow Ablative Therapy with Stem Cell Rescue for Metastatic Breast Cancer

机译：白细胞介素-2（IL-2）作为早期巩固治疗转移性乳腺癌干细胞移植治疗后随机试验

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Interleukin-2 (IL-2) has the capacity to activate lymphocytes to kill multi-drug resistant cancer cells. Our phase I data established the feasibility of administering a single course of low-dose IL-2 (1.6 million 1U/m2/day as a continuous i.v. infusion for 18 days) as consolidation treatment to patients with metastatic breast cancer early after intensive chemotherapy. We are performing a phase I1 trial of AC+T chemotherapy followed by IL-2 consolidation (1 cycle as described above) in high risk stage I1 and 111 breast cancer patients. Disease free survival and toxicity assessment represent major clinical aims (Specific aim 1). Immunologic effectors mechanisms induced following MAT/SR by IL-2 infusion are being evaluated (Aim 2). This study opened 6/11/03. Twelve patients been have accrued, 11 have completed planned treatment, 3 others are being screened. Two additional institutional sites are being added. Toxicity has been minimal to none. Two additional patients are being- screened for enrollment. Laboratory correlation studies are proceeding Our plan is complete accrual within 2 years, carrying over funds from preceding years.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号